With this definition, we confirmed previous reports showing that, compared with CML-BP, de novo BCR::ABL1+AML present with fewer additional chromosomal abnormalities, no ABL1 mutations and a sizeable frequency of NPM1 co-mutations [5, 7, 14, 15]. This evidence concerns the gene ABL1 and acute myeloid leukemia.